Cost-Effectiveness of saxagliptin versus acarbose as second-Line therapy in type 2 diabetes in China

PLoS ONE

Volumn 11, Issue 11, 2016, Pages

  Gu, Shuyan ^a   Zeng, Yuhang ^a   Yu, Demin ^b   Hu, Xiaoqian ^a   Dong, Hengjin ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; HEMOGLOBIN A1C; METFORMIN; SAXAGLIPTIN; ADAMANTANE; DIPEPTIDE;

ADD ON THERAPY; ARTICLE; BODY MASS; CEREBROVASCULAR ACCIDENT; CHINA; CONGESTIVE HEART FAILURE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; GASTROINTESTINAL DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WEIGHT GAIN; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COST; ECONOMIC MODEL; ECONOMICS; FEMALE; MALE; MORTALITY; QUALITY OF LIFE;

ADAMANTANE; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CHINA; COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIA; MALE; METFORMIN; MODELS, ECONOMIC; QUALITY OF LIFE;

EID: 84995897739     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0167190     Document Type: Article

References (70)

1. International Diabetes Federation. IDF Diabetes Atlas, 2014 Update. Available: https://www.idf.org/ sites/default/files/Atlas-poster-2014-EN.pdf. Accessed 16 April 2015.
2. Fall CH. Non-industrialised countries and affluence. Br Med Bull. 2001; 60: 33-50. PMID: 11809617
3. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013; 310: 948-959. doi: 10.1001/jama.2013.168118 PMID: 24002281
4. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014; 37 Suppl 1: S14-S80.
5. Chinese Diabetes Society. Chinese guideline for type 2 diabetes prevention (2013). Chinese Journal of Diabetes. 2014; 22: 2-42.
6. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35: 1364-1379. doi: 10.2337/dc12-0413 PMID: 22517736
7. Alvarez GF, Tofe PS, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab. 2008; 10 Suppl 1: 25-32.
8. Larkin A, Hoffman C, Stevens A, Douglas A, Bloomgarden Z. Determinants of Adherence to Diabetes Treatment. J Diabetes. 2015; 7: 864-871. doi: 10.1111/1753-0407.12264 PMID: 25565088
9. Lundkvist J, Berne C, Bolinder B, Jonsson L. The economic and quality of life impact of hypoglycemia. Eur J Health Econ. 2005; 6: 197-202. doi: 10.1007/s10198-005-0276-3 PMID: 15761775
10. Pi-Sunyer FX. The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med. 2009; 121: 94-107. doi: 10.3810/pgm.2009.09.2056 PMID: 19820278
11. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005; 43: 521-530. PMID: 15908846
12. Currie CJ, Peyrot M, Morgan CL, Poole CD, Jenkins-Jones S, Rubin RR, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012; 35: 1279-1284. doi: 10.2337/dc11-1277 PMID: 22511257
13. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. ARCHIVES OF INTERNAL MEDICINE. 2006; 166: 1836-1841. doi: 10.1001/archinte.166.17.1836 PMID: 17000939
14. Krapek K, King K, Warren SS, George KG, Caputo DA, Mihelich K, et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother. 2004; 38: 1357-1362. doi: 10.1345/ aph.1D612 PMID: 15238621
15. Kuo YF, Raji MA, Markides KS, Ray LA, Espino DV, Goodwin JS. Inconsistent use of diabetes medications, diabetes complications, and mortality in older Mexican Americans over a 7-year period: data from the Hispanic established population for the epidemiologic study of the elderly. Diabetes Care. 2003; 26: 3054-3060. PMID: 14578239
16. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004; 27: 2800-2805. PMID: 15562188
17. Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther. 2003; 25: 2958-2971. PMID: 14693318
18. White TJ, Vanderplas A, Chang E, Dezii CM, Abrams GD. The costs of non-adherence to oral antihyperglycemic medication in individuals with diabetes Mellitus and concomitant diabetes mellitus and cardiovascular disease in a managed care environment. DISEASE MANAGEMENT & HEALTH OUTCOMES. 2004; 12: 181-188.
19. Miller BR, Nguyen H, Hu CJ, Lin C, Nguyen QT. New and emerging drugs and targets for type 2 diabetes: reviewing the evidence. Am Health Drug Benefits. 2014; 7: 452-463. PMID: 25558307
20. Tunceli K, Zhao C, Davies MJ, Brodovicz KG, Alexander CM, Iglay K, et al. Factors associated with adherence to oral antihyperglycemic monotherapy in patients with type 2 diabetes. Patient Prefer Adherence. 2015; 9: 191-197. doi: 10.2147/PPA.S71346 PMID: 25670888
21. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med. 2002; 19: 279-284. PMID: 11942998
22. Standl E, Schnell O. Alpha-glucosidase inhibitors 2012-cardiovascular considerations and trial evaluation. Diab Vasc Dis Res. 2012; 9: 163-169. doi: 10.1177/1479164112441524 PMID: 22508699
23. Ghadyale V, Takalikar S, Haldavnekar V, Arvindekar A. Effective Control of Postprandial Glucose Level through Inhibition of Intestinal Alpha Glucosidase by Cymbopogon martinii (Roxb.). Evid Based Complement Alternat Med. 2012; 2012: 372909. doi: 10.1155/2012/372909 PMID: 21792369
24. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193-203. doi: 10.2337/dc08-9025 PMID: 18945920
25. Scheen AJ. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs. 2003; 63: 933-951. PMID: 12699398
26. Hanefeld M. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc Diabetol. 2007; 6: 20. doi: 10.1186/1475-2840-6-20 PMID: 17697384
27. Bayer. Glucobay 50mg tablets- 4. Clinical particulars. Available: http://www.medicines.org.uk/emc/ medicine/19972. Accessed 12 December 2015.
28. Toth PP. Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease. Vasc Health Risk Manag. 2015; 11: 9-23. doi: 10. 2147/VHRM.S75215 PMID: 25565858
29. Kania DS, Gonzalvo JD, Weber ZA. Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus. Clin Ther. 2011; 33: 1005-1022. doi: 10.1016/j.clinthera.2011.06.016 PMID: 21802144
30. Kulasa K, Edelman S. Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid. 2010; 5: 23-37. PMID: 21042540
31. Neumiller JJ. Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes. Clin Diabetes. 2014; 32: 170-177. doi: 10.2337/diaclin.32.4.170 PMID: 25646943
32. AstraZeneca. Onglyza 2.5mg & 5mg film-coated tablets- 4. Clinical particulars. Available: http://www. medicines.org.uk/emc/medicine/22315. Accessed 12 December 2015.
33. Lv CF, Yu P, Zhou SJ, Li CJ, Lv L, Chen R, et al. Efficacy and safety of saxagliptin combined metformin in newly diagnosed type 2 diabetes mellitus patients. Chinese Journal of Diabetes Mellitus. 2013; 5: 759-762.
34. McEwan P, Bergenheim K, Yuan Y, Tetlow AP, Gordon JP. Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in diabetes care. Pharmacoeconomics. 2010; 28: 665-674. doi: 10.2165/11535350-000000000-00000 PMID: 20524723
35. McEwan P, Evans M, Bergenheim K. A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab. 2010; 12: 623-630. doi: 10.1111/j.1463-1326.2010.01198.x PMID: 20590737
36. McEwan P, Peters JR, Bergenheim K, Currie CJ. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin. 2006; 22: 121-129. doi: 10.1185/030079906X80350 PMID: 16393438
37. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004; 47: 1747-1759. doi: 10.1007/ s00125-004-1527-z PMID: 15517152
38. National Health And Family Planning Commission Of The People's Republic Of China. China health statistics yearbook 2013. Beijing, China. 2013. Available: http://www.nhfpc.gov.cn/htmlfiles/zwgkzt/ ptjnj/year2013/index2013.html. Accessed 20 April 2015.
39. World Health Organization. The world health report 2002- Chapter 5 (Some Strategies to Reduce Risk-Technical considerations for cost-effectiveness analysis). Available: http://www.who.int/whr/2002/en/ Chapter5.pdf?ua=1. Accessed 9 April 2015.
40. Zheng YM, Wu J, Xie K. Incidence and cost of hypoglycemia episode in patients with type 2 diabetes mellitus (T2DM). Chinese Rural Health Service Administration. 2012; 32: 1195-1198.
41. Qian D. Efficacy and safety of saxagliptin combined with metformin in the treatment of the patients with newly diagnosed type 2 diabetes. Chinese Journal of Coal Industry Medicine. 2015; 18: 23-26, 27.
42. Wang MM, Lin S, Chen YM, Shu J, Lu HY, Zhang YJ, et al. Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin. Diabetes Res Clin Pract. 2015; 108: e67-e70. doi: 10.1016/j.diabres.2015.02.022 PMID: 25841300
43. Qiao Y, Zhao J, He M, Wang X. Effect of metformin combined with saxagliptin on insulin resistance of newly diagnosed patients with type 2 diabetes. Journal of Practical Diabetology. 2016; 12: 48-50.
44. Wang W, Chen Y, Qian T, Yao W. Effect of saxagliptin combined with metformin on blood glucose, blood pressure and glycosylated hemoglobin of aged patients with type 2 diabetes. Chinese Journal of Gerontology. 2016; 36: 332-333.
45. General Administration of Sport of China. National Physique Monitoring Bulletin (2010). Available: http://www.sport.gov.cn/n16/n1077/n297454/2052709.html. Accessed 29 December 2014.
46. Ji L, Hu D, Pan C, Weng J, Huo Y, Ma C, et al. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. Am J Med. 2013; 126: 911-925.
47. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010; 14: 1-248.
48. National Bureau of Statistics of the People's Republic of China. Consumer price index of residents. Available: http://data.stats.gov.cn/workspace/index?m=hgnd. Accessed 28 November 2014.
49. Price Bureau. Official drug price list for saxagliptin. Available: http://www.zjpi.gov.cn/main/html/2014/ CT10046/eec3f13a8b2d46258a93966273078df7.html. Accessed 27 December 2014.
50. Price Bureau. Official drug price list for acarbose. Available: http://www.zjpi.gov.cn/main/html/2014/ CT10046/dd72e4240a7e4c1da820a849642f7b37.html. Accessed 27 December 2014.
51. Hou XY, Zen Z, Tao X, Zhang CA, Shi YQ, Zheng JY. Cost-effectiveness analysis of 2 dosage forms of metformin hydrochloride in the treatment of type 2 diabetes. China Pharmacy. 2014: 1844-1847.
52. Gao L, Zhao FL, Li SC. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China. Int J Technol Assess Health Care. 2012; 28: 436-444. doi: 10.1017/ S0266462312000608 PMID: 23006540
53. Li HC, Xu F, Wang F. Cost-effectiveness of biphasic insulin aspart 30 combined with metformin in patients with type 2 diabetes mellitus. Chinese Journal of New Drugs. 2011; 20: 2163-2170.
54. Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, et al. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Adv Ther. 2008; 25: 752-774. doi: 10.1007/s12325-008-0080-4 PMID: 18704282
55. Guo H, Li J, Jiang ZL. Follow-up effects of the increased physical activity on the glucolipid metabolic factors and medical costs in type 2 diabetic patients. Chinese Journal of Rehabilitation Medicine. 2007; 22: 395-398.
56. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002; 22: 340-349. PMID: 12150599
57. Currie CJ, McEwan P, Peters JR, Patel TC, Dixon S. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health. 2005; 8: 581-590. doi: 10.1111/j.1524-4733.2005.00046.x PMID: 16176496
58. Lane S, Levy AR, Mukherjee J, Sambrook J, Tildesley H. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. CURRENT MEDICAL RESEARCH AND OPIN-ION. 2014; 30: 1267-1273.
59. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of healthrelated utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006; 22: 1523-1534. doi: 10.1185/030079906X115757 PMID: 16870077
60. Matza LS, Boye KS, Yurgin N, Brewster-Jordan J, Mannix S, Shorr JM, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res. 2007; 16: 1251-1265. doi: 10.1007/ s11136-007-9226-0 PMID: 17638121
61. National Bureau of Statistics of China. Gross Domestic Product (GDP) per capita. Available: http://data. stats.gov.cn/easyquery.htm?cn=C01&zb=A0201&sj=2014. Accessed 28 January 2016.
62. Pan C, Yang W, Barona JP, Wang Y, Niggli M, Mohideen P, et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med. 2008; 25: 435-441. doi: 10.1111/j.1464-5491.2008.02391.x PMID: 18341596
63. Li CJ, Liu XJ, Bai L, Yu Q, Zhang QM, Yu P, et al. Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetol Metab Syndr. 2014; 6: 69. doi: 10.1186/ 1758-5996-6-69 PMID: 24917890
64. McIntosh B, Cameron C, Singh SR, Yu C, Ahuja T, Welton NJ, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 2011; 5: e35-e48. PMID: 22046219
65. McIntosh B, Cameron C, Singh SR, Yu C, Dolovich L, Houlden R. Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 2012; 6: e62-e74. PMID: 23696771
66. Zintzaras E, Miligkos M, Ziakas P, Balk EM, Mademtzoglou D, Doxani C, et al. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis. Clin Ther. 2014; 36: 1443-1453. doi: 10.1016/j.clinthera.2014.06.035 PMID: 25109773
67. Bodegard J, Sundstrom J, Svennblad B, Ostgren CJ, Nilsson PM, Johansson G. Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: a cohort study of 8486 primary-care patients. Diabetes Metab. 2013; 39: 306-313. doi: 10.1016/j.diabet.2013. 05.004 PMID: 23871502
68. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353: 487-497. doi: 10.1056/ NEJMra050100 PMID: 16079372
69. Zullig LL, Gellad WF, Moaddeb J, Crowley MJ, Shrank W, Granger BB, et al. Improving diabetes medication adherence: successful, scalable interventions. Patient Prefer Adherence. 2015; 9: 139-149. doi: 10.2147/PPA.S69651 PMID: 25670885
70. Yu ZJ. Clinical analysis on factors associated with medication adherence of type 2 diabetes. Guide of China Medicine. 2011; 09: 65-66.